NM107

SKU: orb1299970

Description

NM107 (2'-C-Methylcytidine) is a broad-spectrum antiviral nucleoside analog that potently inhibits HCV NS5B RNA-dependent RNA polymerase, demonstrating an EC50 of 1.85 μM in wild-type replicon assays. It serves as a key research tool for studying hepatitis C virus replication mechanisms and the development of nucleoside-based antiviral therapies in both in vitro and in vivo experimental models.

Research Area

Infectious Disease & Virology, Protein Biochemistry

Key Properties

• CAS Number: 20724-73-6
• MW: 257.24
• Purity: 98.00% (May vary between batches)
• Formula: C₁₀H₁₅N₃O₅
• SMILES: C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1n1ccc(N)nc1=O
• Target: HCV Protease
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (7.77 mM);H2O:50 mg/mL (194.37 mM)

Bioactivity

• In Vivo:
  Prolonged norovirus shedding may occur in certain patients, such as organ transplant recipients. Established a mouse model for persistent norovirus infection (using the mouse norovirus MNV.CR6 strain). The nucleoside viral polymerase inhibitor 2′-C-methylcytidine (2CMC), but not favipiravir (T-705), reduced viral shedding to undetectable levels. Viral rebound was observed after stopping treatment, which was again effectively controlled by treatment with 2CMC. No drug-resistant variants emerged.
  Read more...
• In Vitro:
  NM107 reduces the number of viral plaques in BHK-21 cells infected with dengue type 2, reovirus type 1, West Nile, and yellow fever RNA viruses with EC50 values of 95, 26, 80, and 75 μM, respectively. NM107 inhibits hepatitis C virus (HCV) replication (EC50 = 2.2 μM in a replicon assay) and protects MDBK cells from infection with bovine virus diarrhea virus (BVDV; EC50 = 2.2 μM) and human corona virus (HCoV; EC50 = 90 μM). It also reduces infectious virus yield in BHK-21 cells infected with foot-and-mouth disease virus (FMDV; EC50 = 6.4 μM) and swine vesicular disease virus (SVDV; EC50 = 45.2 μM).
  Read more...
• Animal Research:
  For all experiments, age- and sex-matched mice 8 to 12 weeks of age were infected by oral gavage with 10^6 CCID50 (50% cell culture infective doses) of CR6. At 7 days postinfection (p.i.), mice were left untreated (n = 9) or were treated with 100 mg/kg daily of 2'-C-Methylcytidine(2CMC) subcutaneously for 5 (n = 4), 7 (n = 4), or 11 (n = 4) days. Two more rounds of a 14-day treatment (with an ～4-week interval in between) with 2CMC (n = 10) or favipiravir (200 mg/kg daily by oral gavage [n = 5]) were given. On each day after infection, the general condition and weight of treated and untreated mice were assessed, individual stool samples were collected (whenever possible during one daily period of observation), and levels of MNV RNA were quantified by reverse transcriptase quantitative PCR (RT-qPCR).
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

2'-C-Methylcytidine, HCVProtease, HCV Protease, HCV, Hepatitis C virus, Inhibitor, inhibit, NM 107, NM107, NM-107

Compound Identifiers

PubChem CID

500902